Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071492 | 0.90 | POLB (0.53) | CNR1CYP1A2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL6433557 | 0.84 | KDM4E (0.61) | CYP1A2CYP2D6CYP2C19MAPTGAA | |
| SCHEMBL14640609 | 0.84 | CNR1 (0.58) | CNR1CYP1A2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL4179064 | 0.84 | HPGD (0.57) | CNR1NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL14991977 | 0.83 | CNR2 (0.47) | CNR1MAPTGAAPLAAT3PLAAT5 | |
| SCHEMBL14141265 | 0.83 | NPC1 (0.59) | CNR1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4700346 | 0.83 | ESRRG (0.54) | SMN1; SMN2GFER | |
| SCHEMBL4702861 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5553483 | 0.83 | PLAAT3 (0.58) | CNR1SMN1; SMN2TAAR1PLAAT3PLAAT5 | |
| SCHEMBL419646 | 0.83 | CNR1 (0.50) | CNR1SMN1; SMN2TAAR1PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2374796-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | claimed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| EP-4320121-A2 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF | LifeArc (GB) | 2024-02-14 | — | — | EP | disclosed |
| CN-117545751-A | 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use | 生命爱科 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-1557409-A1 | 5HT2C receptor modulators | Arena Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | CNR1 27/4885CYP1A2 108/4885CYP2D6 197/4885 |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | CNR1 3352/4885CYP1A2 3561/4885CYP2D6 3877/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | CNR1 55/4885CYP1A2 252/4885CYP2D6 444/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | CNR1 3209/4885CYP1A2 3776/4885CYP2D6 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.